Takeda’s Dengue Vaccine Is Effective in Late-Stage Study
Vaccine is effective in preventing insect-borne dengue fever
Drugmaker is advancing with efforts to support shot’s launchTakeda Pharmaceutical Co.’s experimental dengue vaccine hit its main goal in a late-stage study, showing it’s effective in preventing the mosquito-borne virus that afflicts roughly 400 million people a year.
The vaccine prevented all four strains of dengue virus from causing the potentially lethal illness, also known as break-bone fever, the Japanese drugmaker said in a statement Tuesday. While studies so far haven’t raised significant safety concerns, a review of the data will continue, Takeda said.
The findings provide a boost to Takeda’s ambition to tackle the disease, which kills about 20,000 people annually, and avoid setbacks that rival Sanofi encountered after spending more than two decades and 1.5 billion euros ($1.7 billion) getting the world’s first dengue vaccine to the market.
– Bloomberg
https://www.takeda.com/jp/newsroom/newsreleases/2019/20190130-8043/
https://www.bloomberg.co.jp/news/articles/2019-01-29/PM44M26KLVR701